Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
NeOnc Technologies HoldingsNTHI -4.21%7 ROC (Joel Greenblatt) % is -8,931.05% as of Mar. 2026. GuruFocus rates NTHI with a GF Score™ of 7/100. The stock has 1 warning sign investors should review. Among 1,323 Biotechnology companies, NeOnc Technologies Holdings ranks worse than 89.95% on this metric.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits). He defines ROC (Joel Greenblatt) % as EBIT divided by the total of Property, Plant and Equipment and net working capital. NeOnc Technologies Holdings's annualized ROC (Joel Greenblatt) % for the quarter that ended in Mar. 2026 was -8,931.05%.
The historical rank and industry rank for NeOnc Technologies Holdings's ROC (Joel Greenblatt) % or its related term are showing as below:
NTHI'
s ROC (Joel Greenblatt) % Range Over the Past 10 Years
Min: -38920.83 Med: -34951.85 Max: -9584.05
Current: -9584.05
During the past 5 years, NeOnc Technologies Holdings's highest ROC (Joel Greenblatt) % was -9584.05%. The lowest was -38920.83%. And the median was -34951.85%.
NTHI's ROC (Joel Greenblatt) % is ranked worse than 89.95% of 1323
companies
in the Biotechnology industry
Industry Median: -296.6
vs NTHI: -9584.05
The way Joel Greenblatt defines Return on Capital is a more accurate measure of how efficiently the company generates returns onthe capital actually invested in the business. EBIT is used instead of net income because the tax and interest payment may be affected by factors other than the core business operation. Intangible assets are not included in the calculation because they don't need to be replaced.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
NTHI vs GUTS, PEPG, ENGN: ROC (Joel Greenblatt) % Comparison
For the Biotechnology subindustry, NeOnc Technologies Holdings's ROC (Joel Greenblatt) %, along with its competitors' market caps and ROC (Joel Greenblatt) % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NeOnc Technologies Holdings ROC (Joel Greenblatt) % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, NeOnc Technologies Holdings's ROC (Joel Greenblatt) % distribution charts can be found below:
* The bar in red indicates where NeOnc Technologies Holdings's ROC (Joel Greenblatt) % falls into.
Joel Greenblatt defined Return on Capital differently in his book The Little Book That Still Beats the Market (Little Books. Big Profits) . He defines Return on Capital as follows:
EBIT stands for Earnings Before Interest and Taxes.
Fixed Assets are also known as non-current assets. They include the Property, Plant and Equipment that the firm needs in its operation.
GuruFocus calculates net working capital as: (Accounts Receivable + Total Inventories + Other Current Assets) - (Accounts Payable & Accrued Expense + Deferred Revenue + Other Current Liabilities). We're trying to account for OPERATING assets and liabilities (part of daily business) when calculating working capital. Cash and marketable securities are considered NON-OPERATING assets and are not included in calculation. We will also back out all interest bearing debt, short term debt and the portion of long term debt that is due in the current period from the current liabilities. This debt will be considered when computing cost of capital and it would be inappropriate to count it twice.
Note:
The EBIT data used here is four times the quarterly (Mar. 2026) EBIT data.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROC (Joel Greenblatt) % of -8,931.05% mean?
NeOnc Technologies Holdings (NTHI) has a ROC (Joel Greenblatt) % of -8,931.05% as of Mar. 2026. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on NeOnc Technologies Holdings and its competitors. According to the industry distribution chart, NeOnc Technologies Holdings ranks #1190 out of 1323 companies in the Biotechnology industry, placing it in the top 89.9%.
Is NeOnc Technologies Holdings' ROC (Joel Greenblatt) % too high?
NeOnc Technologies Holdings' current ROC (Joel Greenblatt) % is -8,931.05%. Based on the distribution chart, NeOnc Technologies Holdings ranks #1190 out of 1323 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, NeOnc Technologies Holdings has a GF Score™ of 7/100, reflecting its overall financial health beyond just this single metric.
How does NeOnc Technologies Holdings' ROC (Joel Greenblatt) % compare to GUTS and PEPG?
According to the Biotechnology industry distribution chart, NeOnc Technologies Holdings ranks #1190 out of 1323 companies for ROC (Joel Greenblatt) %. This places NeOnc Technologies Holdings in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROC (Joel Greenblatt) % for a Biotechnology company?
A good ROC (Joel Greenblatt) % depends on the Biotechnology industry context. However, ROC (Joel Greenblatt) % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROC (Joel Greenblatt) % mean?
A high ROC (Joel Greenblatt) % can signal that a stock is expensive relative to its fundamentals. Joel Greenblatt's return on capital is the ratio of EBIT to average fixed assets and net working capital. View historical data on NeOnc Technologies Holdings and its competitors. NeOnc Technologies Holdings's current ROC (Joel Greenblatt) % is -8,931.05%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NeOnc Technologies Holdings stock overvalued right now?
NeOnc Technologies Holdings (NTHI) has a current ROC (Joel Greenblatt) % of -8,931.05%. The current ROC (Joel Greenblatt) % is -8,931.05%. NeOnc Technologies Holdings' overall GF Score™ is 7/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROC (Joel Greenblatt) % calculated?
ROC (Joel Greenblatt) % is calculated from a company's financial statements. For NeOnc Technologies Holdings (NTHI), the current ROC (Joel Greenblatt) % is -8,931.05% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
NeOnc Technologies Holdings Inc. is a clinical-stage biopharmaceutical company focused on developing novel molecular technologies for the targeted delivery of therapeutics to treat central nervous system diseases. The company is developing drug delivery methods and drug candidates for intracranial malignancies such as gliomas, glioblastoma, and meningioma. Its lead product candidates include NEO100, an intranasal drug delivery therapy for brain cancer patients, and NEO212, an oral chemical conjugate designed to enhance treatment for glioblastoma.
7GF Score
Get the complete analysis for NTHI
ROC (Joel Greenblatt) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NTHI has been successfully added to your 
